Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06694181 · ClinicalTrials.gov registry record
Safe and Explainable AI
A clinical trial of Breast Cancer and Sepsis, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 300,000
- Enrollment target
- 1
- Study location
NCT06694181: Recruiting study of Breast Cancer and Sepsis, sponsored by Abramson Cancer Center at Penn Medicine.
NCT06694181 is a study of Breast Cancer and Sepsis that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 300,000 participants, above the 2,558-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (11628% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06694181, a study of Breast Cancer and Sepsis, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 300,000 participants
- Enrollment target
- 1
- Study location
Study Summary
While current AI technology is suitable for automating some repetitive clinical tasks, technical challenges remain in solving critical and gainful problems in the domains of patient and disease management. The proposed research seeks to address issues in medical AI, such as integrating medical knowledge effectively, making AI recommendations explainable to clinicians, and establishing safety guarantees.
Primary Outcome
Develop and evaluate novel algorithms for training neurosymbolic models. We will develop data- and compute-efficient algorithms for end-to-end training of neurosymbolic models. This task will reduce the burden on clinician experts to provide fine-grained labels on voluminous EHR data.
Conditions Studied
Interventions
- OTHER AI-PERSONALIZED CLINICAL DECISION SUPPORT
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300,000 participants |
| Start Date | 2025-11-29 |
| Est. Completion | 2028-11 |
What NCT06694181 shows while recruiting
NCT06694181 is an observational study that tracks outcomes without assigning an intervention. Its 300,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,558-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (11628% higher).
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AI-PERSONALIZED CLINICAL DECISION SUPPORT is the first listed.
NCT06694181 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06694181 about?
NCT06694181 is a clinical study titled "Safe and Explainable AI". While current AI technology is suitable for automating some repetitive clinical tasks, technical challenges remain in solving critical and gainful problems in the domains of patient and disease management. The proposed research seeks to address issues in medical AI, such as integrating medical knowl...
What is the current status of trial NCT06694181?
This trial is currently recruiting. The enrollment target is 300,000 participants. The study started on 2025-11-29. Estimated completion is 2028-11.
What conditions does trial NCT06694181 study?
This clinical trial studies the following conditions: Breast Cancer, Sepsis, Cardiology, Artifical Inteligence.
What interventions are being tested in trial NCT06694181?
The interventions under investigation include: AI-PERSONALIZED CLINICAL DECISION SUPPORT (OTHER).
Who is sponsoring clinical trial NCT06694181?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06694181 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06694181's enrollment target sits among peer trials
300,000 2nd of 1224 the highest of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT07314697 · 300,000 participants · NA
Arrival Time Implementation
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
- NCT05668637 · 318,542 participants
Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI